Director at BridgeBio Oncology (BBOT) granted options for 31,675 shares
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics director Praveen P. Tipirneni received a stock option grant for 31,675 shares of Common Stock. The option has an exercise price of $7.73 per share and expires on June 15, 2036. It vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, subject to his continued service. Following this grant, he holds options for 31,675 shares directly, with no open-market buying or selling reported in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Tipirneni Praveen P.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 31,675 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 31,675 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option Shares Granted: 31,675 shares
Exercise Price: $7.73 per share
Expiration Date: June 15, 2036
+1 more
4 metrics
Option Shares Granted
31,675 shares
Stock Option (Right to Buy) grant to director
Exercise Price
$7.73 per share
Stock option exercise price for Common Stock
Expiration Date
June 15, 2036
Option expiration for granted stock options
Shares Underlying Options After Grant
31,675 shares
Total derivative shares following transaction
Key Terms
Stock Option (Right to Buy), Common Stock, exercise price, vest in full, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 7.7300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"The shares underlying the stock option vest in full upon the earlier"
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did BBOT director Praveen P. Tipirneni report?
Director Praveen P. Tipirneni reported receiving a stock option grant for 31,675 shares of BridgeBio Oncology Therapeutics Common Stock. This was a compensation-related award, not an open-market share purchase or sale, and is recorded as a derivative acquisition.
What is the exercise price of the new BBOT stock options?
The granted stock options have an exercise price of $7.73 per share. This means Tipirneni can buy BridgeBio Oncology Therapeutics Common Stock at $7.73 if he exercises the options after they vest and before they expire.
When do Praveen Tipirneni’s BridgeBio Oncology options vest?
The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders. Vesting is conditioned on Tipirneni’s continued service to BridgeBio Oncology Therapeutics through the applicable vesting date.
When do the reported BBOT stock options expire?
The reported stock options expire on June 15, 2036. If they are not exercised by that expiration date, Tipirneni will lose the right to purchase BridgeBio Oncology Therapeutics shares at the $7.73 exercise price granted.
How many BBOT derivative securities does Tipirneni hold after this grant?
After this grant, Tipirneni holds stock options for 31,675 shares of BridgeBio Oncology Therapeutics Common Stock directly. The Form 4 does not show additional derivative positions, and there were no reported open-market buys or sells in this filing.